A Post Marketing Safety Study of Sitagliptin (JANUVIA®) (MK-0431-234)

Merck Sharp & Dohme LLC2,974 enrolled

Overview

The primary objective of this study is to obtain safety information on the use of sitagliptin (JANUVIA®) from endocrinologists, diabetologists, internists, and general practitioners.

Study Type

OBSERVATIONAL

Enrollment

2,974

Conditions

Diabetes Mellitus, Type 2

Interventions

Sitagliptin (JANUVIA®)DRUG

Participants prescribed Sitagliptin (JANUVIA®) in routine clinical practice.

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: \- Must be taking sitagliptin (JANUVIA™) for the treatment of type 2 diabetes mellitus \- Treating physician must agree to provide information regarding the participants treatment

Outcomes

Primary Outcomes

Number of Participants With an Adverse Event

Time frame: Up to approximately 28 months

Age of Participants Prescribed Sitagliptin

Time frame: Up to approximately 28 months

Number of Participants With Concomitant Therapies

Time frame: Up to approximately 28 months

Number of Participants With Concomitant Conditions

Time frame: Up to approximately 28 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.